|
Description:
|
|
In this special edition of Diabetes Core Update, host Neil Skolnik, MD, explores the timely and critical topic of compounded medications in diabetes care. Dr. Skolnik is joined by John Hertig, PharmD, MS, CPPS, Associate Professor at the Butler University College of Pharmacy and Health Sciences, and Ed Hernandez, Executive Vice President and President of Manufacturing Operations at Eli Lilly & Company. Together, they discuss the role of compounded medications, the benefits and risks associated with their use, and the importance of ensuring quality and safety standards in the compounding process. This episode offers valuable insights for clinicians navigating the complexities of compounded therapies and provides practical considerations for patient care. This special edition of Diabetes Core Update is supported by Lilly. Presented by: - Neil Skolnik, MD – Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health
- John Hertig, PharmD, MS, CPPS – Associate Professor, Butler University College of Pharmacy and Health Sciences
- Ed Hernandez – Executive Vice President, Eli Lilly & Company; President of Manufacturing Operations at Lilly
Selected References: Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care December 2, 2024; dci240091 https://doi.org/10.2337/dci24-0091 PubMed: 39620926 FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. US FDA Website ( current as of 12/18/2024) |
.png)
More
Religion & Spirituality
Education
Arts and Design
Health
Fashion & Beauty
Government & Organizations
Kids & family
Music
News & Politics
Science & Medicine
Society & Culture
Sports & Recreation
TV & Film
Technology
Philosophy
Storytelling
Horror and Paranomal
True Crime
Leisure
Travel
Fiction
Crypto
Marketing
History
Comedy
Arts
Games & Hobbies
Business
Motivation
